Market Research Logo

Post Menopausal Osteoporosis - Pipeline Review, H2 2015

Post Menopausal Osteoporosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Pipeline Review, H2 2015’, provides an overview of the Post Menopausal Osteoporosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Post Menopausal Osteoporosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Post Menopausal Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis Overview
Therapeutics Development
Pipeline Products for Post Menopausal Osteoporosis - Overview
Post Menopausal Osteoporosis - Therapeutics under Development by Companies
Post Menopausal Osteoporosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Post Menopausal Osteoporosis - Products under Development by Companies
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Amgen Inc.
Chronos Therapeutics Limited
Eli Lilly and Company
Hanmi Pharmaceuticals, Co. Ltd.
Ligand Pharmaceuticals, Inc.
Merck & Co., Inc.
Oncobiologics, Inc.
Paras Biopharmaceuticals Finland Oy
Pfizer Inc.
Radius Health, Inc.
Richter-Helm BioTec GmbH & Co. KG
Unigene Laboratories, Inc. (Inactive)
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aceclofenac + eperisone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abaloparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bazedoxifene acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
blosozumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMD-1111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
calcitonin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Postmenopausal Osteoporosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lasofoxifene tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
odanacatib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
romosozumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
teriparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
teriparatide biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post Menopausal Osteoporosis - Recent Pipeline Updates
Post Menopausal Osteoporosis - Dormant Projects
Post Menopausal Osteoporosis - Discontinued Products
Post Menopausal Osteoporosis - Product Development Milestones
Featured News & Press Releases
Nov 17, 2015: Radius Health Has Submitted a Marketing Authorization Application for the Investigational Drug Abaloparatide-SC for the Treatment of Postmenopausal Osteoporosis in Europe
Oct 19, 2015: Enteris BioPharma’s Formulation Technology Enables Oral Delivery of Tarsa Therapeutics’ TBRIA - the First Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis
Oct 19, 2015: TARSA Therapeutics' NDA For TBRIA, The First Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis, Accepted For Filing
Oct 12, 2015: Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis
Oct 12, 2015: New Data Show Consistent Safety Profile For Up To 10 Years With Prolia In Postmenopausal Women With Osteoporosis
Oct 12, 2015: New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide
Oct 11, 2015: New Data Show Greater Bone Mineral Density Gains With Prolia Compared With Zoledronic Acid
Oct 10, 2015: Radius Health Presents Positive Phase 3 Top-Line Data for Investigational Osteoporosis Therapy Abaloparatide at the American Society for Bone and Mineral Research 2015 Annual Meeting
Oct 09, 2015: Sermonix to Present Scientific Poster Comparing Investigational Drug Lasofoxifene to Raloxifene at American Society for Bone and Mineral Research Annual Meeting
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H2 2015
Post Menopausal Osteoporosis - Pipeline by Chronos Therapeutics Limited, H2 2015
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H2 2015
Post Menopausal Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Post Menopausal Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Post Menopausal Osteoporosis - Pipeline by Merck & Co., Inc., H2 2015
Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H2 2015
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2015
Post Menopausal Osteoporosis - Pipeline by Pfizer Inc., H2 2015
Post Menopausal Osteoporosis - Pipeline by Radius Health, Inc., H2 2015
Post Menopausal Osteoporosis - Pipeline by Richter-Helm BioTec GmbH & Co. KG, H2 2015
Post Menopausal Osteoporosis - Pipeline by Unigene Laboratories, Inc. (Inactive), H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Post Menopausal Osteoporosis Therapeutics - Recent Pipeline Updates, H2 2015
Post Menopausal Osteoporosis - Dormant Projects, H2 2015
Post Menopausal Osteoporosis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report